Mirtazapina Aurovitas Spain (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Aurovitas Spain, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as a tablet (strength unspecified) for oral use. It is indicated for the management of major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapina Aurovitas Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across the European Union and other global markets.

Mirtazapine is a NaSSA antidepressant used primarily in the treatment of depressive disorders.

Major depressive disorder: alleviates depressive symptoms and improves overall functioning.

Mirtazapine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite leading to weight gain - Dry mouth - Constipation - Dizziness - Headache

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Suicidal ideation, especially early in treatment - Severe hypersensitivity reactions (rash, angioedema) - Cardiac arrhythmias (QT prolongation) - Hepatotoxicity

When prescribing mirtazapine, clinicians should consider several safety measures.

Assess for suicidal ideation: monitor patients closely during initiation and dose changes. Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal symptoms. Caution in hepatic impairment: dose adjustment may be required. Use cautiously in elderly: increased risk of sedation and falls. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Store at room temperature: keep below 25°C, in the original packaging, and protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine, tramadol): altered metabolism may occur. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential additive serotonergic effects. - Anticholinergic drugs: may increase anticholinergic burden and worsen dry mouth.